Optimizing PreTerm Infant Ampicillin Dosing
Part of paid clinical trials in Durham, North Carolina.
- Sponsor
- Duke University
- Study ID
- NCT07610486
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Ampicillin
- Early Onset Sepsis
- NICU
- Preterm Neonates
- Safety and Pharmacokinetics
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Days - 7 Days
- Healthy Volunteers
- Not accepted
Interventions
- Ampicillin prescribed by provider per standard of care for evaluation of early onset sepsis — DRUGpreterm infants receive less than 48 hours of prescribed ampicillin (i.e., a "short-course" ampicillin regimen) to provide the desired 48 hours of therapeutic exposures
Study Details
The goal of this clinical trial is to learn if preterm infants who are prescribed antibiotics shortly after birth can safety receive a shorter course of antibiotics (24 to 36 hours instead of 48 hours). The main questions it aims to answer are: * Does short-course ampicillin provide high enough levels of ampicillin at 48 hours? * Is short-course ampicillin safe for preterm infants to receive? Preterm infants who are being prescribed ampicillin by their doctor and enroll in the study will stop ampicillin after a shorter than typical course, and researchers will collect blood samples to measure their ampicillin levels and follow them clinically to see how they do after receiving short-course ampicillin. Participants will: * stop ampicillin earlier than 48 hours (between 24 to 36 hours, depending on how premature they are and the dosing of ampicillin their doctor has prescribed) * have a blood sample collected around 48 hours from when they started ampicillin * have their data collected until 30 days after they receive short-course ampicillin, or until hospital discharge, whichever is sooner
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- May 2026
- Primary completion
- Jul 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Short-course AmpicillinInfants enrolled in the trial receive short-course empiric ampicillin (24 to 36 hours, depending on gestational age and prescribed dosing regimen), rather than a standard (48 hour) empiric ampicillin course
Primary Outcome Measure
Free plasma ampicillin concentration [ Time Frame: data will be collected up to 50 hours from the first dose of ampicillin ]
Central Contacts
- Angelique Boutzoukas, MD, MPH919-668-4733
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Duke Health Neonatal Intensive Care Unit | Durham | North Carolina | 27705 | Stefany Olague, MPH Angelique Boutzoukas, MD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Durham, NC
Related Studies
- Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICURecruiting · Mayo Clinic · Rochester, Minnesota